Vertex Pharmaceuticals announced final results from its Phase 3 STRIVE study of VX-770 for the treatment of cystic fibrosis (CF). The results of STRIVE showed a mean absolute improvement in FEV1 of 10.6% through Week 24 (primary study endpoint) and 10.5% through Week 48 (secondary study endpoint) among patients (n=83) treated with VX-770 vs. placebo. The mean relative improvement from baseline in FEV1 among patients (n=78) treated with VX-770 compared to placebo was 16.9% through Week 48.

Significant improvements in key secondary endpoints in this study were also reported through Week 48. Compared to placebo, patients who received VX-770 experienced a greater average weight gain (7lbs vs. 3.9lbs) and were 55% less likely to experience a pulmonary exacerbation. At Week 2, patients treated with VX-770 experienced an average reduction in sweat chloride of approximately 45 mmol/L which maintained through Week 48. Patients treated with the placebo maintained baseline sweat chloride levels of approximately 100 mmol/L through Week 48. The mean absolute improvement in sweat chloride among those treated with VX-770 was -48.1 mmol/L through Week 48 (P<0.0001).

VX-770 is an oral tablet that directly targets the defective CFTR protein known to cause CF. VX-770 increases the function of defective CFTR protein by increasing the gating activity, or ability to transport ions across the cell membrane, of CFTR once it reaches the cell surface.

For more information call (617) 444-6100 or visit